BR100 Increased By (0.9%)
BR30 Increased By (1%)
KSE100 Increased By (0.93%)
KSE30 Increased By (0.98%)
AGHA 6.38 No Change ▼ 0.00 (0%)
BECO 4.37 Increased By ▲ 0.02 (0.46%)
BML 62.60 Increased By ▲ 0.05 (0.08%)
BOP 31.46 Increased By ▲ 0.07 (0.22%)
CNERGY 11.78 Increased By ▲ 0.05 (0.43%)
CSIL 5.79 Decreased By ▼ -0.12 (-2.03%)
FCCL 61.90 Increased By ▲ 0.19 (0.31%)
FFL 14.86 Increased By ▲ 0.07 (0.47%)
FNEL 1.30 Increased By ▲ 0.06 (4.84%)
KEL 6.35 Increased By ▲ 0.03 (0.47%)
KOSM 5.81 Decreased By ▼ -0.09 (-1.53%)
LOTCHEM 24.79 Increased By ▲ 0.10 (0.41%)
MLCF 106.01 Increased By ▲ 2.08 (2%)
NBP 174.50 Increased By ▲ 1.18 (0.68%)
NCPL 52.60 Increased By ▲ 0.77 (1.49%)
NPL 54.80 Increased By ▲ 0.77 (1.43%)
OGDC 319.00 Increased By ▲ 3.13 (0.99%)
PACE 9.30 Increased By ▲ 0.04 (0.43%)
PAEL 35.81 Increased By ▲ 0.23 (0.65%)
PIBTL 14.24 Increased By ▲ 0.58 (4.25%)
PPL 229.99 Increased By ▲ 3.92 (1.73%)
PRL 81.40 Increased By ▲ 1.12 (1.4%)
PTC 46.80 Increased By ▲ 0.16 (0.34%)
SSGC 24.13 Increased By ▲ 0.31 (1.3%)
TBL 9.36 Increased By ▲ 0.12 (1.3%)
TELE 7.60 Increased By ▲ 0.05 (0.66%)
TPL 24.70 Increased By ▲ 0.16 (0.65%)
TPLP 12.94 Decreased By ▼ -0.05 (-0.38%)
TREET 26.50 Increased By ▲ 0.52 (2%)
TRG 53.75 Increased By ▲ 0.42 (0.79%)

LAHORE: Expressing concern over insufficient healthcare coverage for patients suffering from Multiple Sclerosis (MS) under Punjab’s Sehat Sahulat Programme, health professionals and MS patient have urged Chief Minister Maryam Nawaz to intervene to help them to continue their treatment.

They also urged the chief minister and health authorities to introduce an MS-specific health card to ensure uninterrupted and accessible treatment.

While the Sehat Sahulat programme currently provides up to Rs400,000 in annual healthcare coverage, medical experts say the average annual cost of MS treatment has risen to over one million rupees, placing a financial burden on families.

It may be added that MS is a chronic autoimmune disease that affects young adults aged below 40, particularly women, and causes recurrent attacks, impaired mobility and long-term disability.

Dr Athar Javed, a neurologist says patients are treated with disease-modifying therapies (DMTs), which helps reduce relapses, slow disease progression and improve quality of life. He said a dose is administered every six months, with treatment typically costing around Rs1 million annually. He warns that interruptions in treatment can trigger relapses and potentially lead to irreversible disability.

Punjab Health Initiative Management Company (PHIMC) Chief Executive Officer Dr Ali Razaque, denied the suspension of healthcare treatment for MS patients. He said that the government would continue the treatment without any pause and the amount could be increased in the future depending upon the availability of the health budget.

When asked about the funding, he said patients generally receive Rs400,000 annually, which covers one dose of DMTs before the funds are exhausted. He said the Punjab government is focusing on increasing funding for other health initiatives, including programmes for autoimmune diseases.

Copyright Business Recorder, 2026

Comments

200 characters remaining